We are proud to have supported TAHO Pharmaceuticals Ltd. (TAHO) in the successful submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TAH3311, the first orodispersible film formulation of apixaban.

This submission marks an important milestone for TAHO and a promising advancement in the field of anticoagulant therapy. TAH3311 has the potential to improve treatment adherence and accessibility for patients who have difficulty swallowing conventional tablets, addressing a critical unmet need in this therapeutic space.

3D-PharmXchange provided end-to-end regulatory and strategic support throughout the development and submission process, ensuring that TAHO’s regulatory pathway was both robust and efficient. Our team worked closely with TAHO to align development activities, prepare documentation, and guide the submission strategy.

We congratulate the TAHO team on this achievement and are pleased to be part of their continued journey to bring innovative treatment options to patients.

Read the full announcement from TAHO at this link.